News Image

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

Provided By GlobeNewswire

Last update: Apr 29, 2024

MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it received a positive jury trial verdict of $34 million associated with the patent infringement case it filed on September 16, 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, "Alcon") in the U.S. District Court for the District of Delaware. Sight Sciences asserted that Alcon’s and Ivantis’ sale of the Hydrus® Microstent infringed three key patents.

Read more at globenewswire.com

SIGHT SCIENCES INC

NASDAQ:SGHT (7/18/2025, 8:11:58 PM)

After market: 3.5 0 (0%)

3.5

-0.04 (-1.13%)



Find more stocks in the Stock Screener

Follow ChartMill for more